The Cystic Fibrosis Foundation has launched a new program that will fund 60 additional research coordinators to help speed the progress of CF clinical trials throughout its Therapeutics Development Network (TDN).
Site Search
Showing 21 - 23 of 23 results
News
|
Dec. 23, 2014
|
2 min read
This morning, Vertex Pharmaceuticals announced the results from the Phase 3 clinical trials of ivacaftor (Kalydeco™) and lumacaftor (VX-809) in people with two copies of the F508del mutation.
News
|
June 24, 2014
|
4 min read
This is an exciting time in cystic fibrosis clinical research. Not only are there several clinical trials of therapies to treat the underlying cause of CF, but there are also many trials to treat key symptoms of CF and improve quality of life. These include studies of antibiotics and anti-inflammatories to treat lung infections and inflammation, as well as treatments to improve nutrition and digestion.